Advertisement

Topics

Tibotec Therapeutics Company Profile

15:07 EDT 29th March 2017 | BioPortfolio


News Articles [1810 Associated News Articles listed on BioPortfolio]

Research Reports Initiation on Biotech Stocks -- Regulus Therapeutics, Abeona Therapeutics, ...

Regulus Therapeutics  San Diego, Californiaheadquartered Regulus Therapeutics Inc.'s stock finished Thursday's session 2.08% lower at $2.35with a total trading volume of 187,480 Read more...

Research Reports Coverage on Biotech Stocks -- Celldex Therapeutics, Amicus Therapeutics, ...

http://stock-callers.com/registration Celldex Therapeutics  On Thursday, shares in Hampton, New Jerseyheadquartered Celldex Therapeutics Inc. recorded a trading volume of 3.36 million shares, whi...

Bicycle Therapeutics signs cancer development deal with CRUK

Cancer Research UK and its commercialisation arm are to work with UK biotech firm Bicycle Therapeutics on a novel approach to targeting cancer. Bicycle Therapeutics has developed a new class of thera...

Magenta Therapeutics Announces $48.5M Financing

NewsMagenta Therapeutics aspires to develop a patient-focused set of therapeutics with the first complete platform that addresses the critical challenges in stem cell transplant.

Biotech Stocks Under Scanner -- PTC Therapeutics, Arena Pharma, BioDelivery Sciences, and Seres ...

http://stock-callers.com/registration PTC Therapeutics  At the close on Tuesday, shares in South Plainfield, New Jerseyheadquartered PTC Therapeutics Inc. dropped 3.06%, ending the day at Read...

Heptares to buy G7 Therapeutics to expand GPCR capabilities

Sosei Group's subsidiary Heptares Therapeutics has agreed to acquire Swiss drugmaker G7 Therapeutics for CHF12m ($11.8m).

Multi-target collaboration across respiratory, cardiovascular and metabolic diseases for Bicycle Therapeutics

Bicycle Therapeutics, which is pioneering a new class of therapeutics based on its proprietary bicyclic…

Deals this week: Spero Therapeutics, BioCryst Pharmaceuticals, Breath Therapeutics Holding

Spero Therapeutics has announced it has raised $51.7m in a series C financing round led by GV (formerly Google Ventures).

Drugs and Medications [0 Results]

None

Clinical Trials [32 Associated Clinical Trials listed on BioPortfolio]

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

The primary objective of this study is to continue to provide Darunavir (DRV) to pediatric patients who previously received DRV in any of three pediatric clinical studies sponsored by Tibo...

TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRV

The primary objective of this study is to continue to provide Darunavir (DRV) to pediatric patients who previously received DRV in any of three pediatric clinical studies sponsored by Tibo...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options

This is an open-label safety study to provide early access to TMC114 for HIV-1 infected patients who have failed and exhausted regimens based on commercially available antiretroviral (ARV)...

TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Children and Adolescents

The primary objective is to continue the provision of etravirine (ETR) for patients who previously received ETR in a clinical pediatric trial sponsored by or in collaboration with Tibotec,...

Companies [1110 Associated Companies listed on BioPortfolio]

Tibotec Inc.

Tibotec Inc., based in Yardley, Pa., USA, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Cork, Ir...

Tibotec, Inc

Tibotec is a pharmaceutical research and development company dedicated to the discovery and development of innovative new drugs for HIV/AIDS and other infectious diseases of high unmet medical need. T...

Tibotec Pharmaceuticals Ltd.

Tibotec Pharmaceuticals Ltd., based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with off...

Tibotec Pharmaceuticals

Tibotec Pharmaceuticals, based in Cork, Ireland, is a pharmaceutical research and development company. The Company's main research and development facilities are in Mechelen, Belgium with offices in Y...

Tibotec Therapeutics

More Information about "Tibotec Therapeutics" on BioPortfolio

We have published hundreds of Tibotec Therapeutics news stories on BioPortfolio along with dozens of Tibotec Therapeutics Clinical Trials and PubMed Articles about Tibotec Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tibotec Therapeutics Companies in our database. You can also find out about relevant Tibotec Therapeutics Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record